scholarly journals Dynamics of Uptake and Metabolism of Small Molecules in Cellular Response Systems

PLoS ONE ◽  
2009 ◽  
Vol 4 (3) ◽  
pp. e4923 ◽  
Author(s):  
Maria Werner ◽  
Szabolcs Semsey ◽  
Kim Sneppen ◽  
Sandeep Krishna
2021 ◽  
Author(s):  
Marjan Barazandeh ◽  
Divya Kriti ◽  
Corey Nislow ◽  
Guri Giaever

Abstract BackgroundChemogenomic profiling is a powerful approach towards understanding the genome-wide cellular response to small molecules. Developed in Saccharomyces cerevisiae, chemogenomic screens provide direct, unbiased identification of drug target candidates as well as genes required for drug resistance. While many laboratories have performed chemogenomic fitness assays, they have not been assessed for reproducibility and accuracy. Here we analyze the two largest independent yeast chemogenomic datasets comprising over 35 million gene-drug interactions and more than 6000 unique chemogenomic profiles; the first from our own academic laboratory and the second from the Novartis Institute of Biomedical Research (NIBR).ResultsCombining the datasets revealed robust genetic interaction response signatures that point to common mechanism of action, despite the substantial differences in experimental and analytical pipelines. We previously reported that the cellular response to small molecules is limited and can be described by a network of 45 chemogenomic signatures. In the present study, we show that the majority of these signatures (66%) are also found in the companion dataset, providing further support for their biological relevance as systems-level, small molecule response systems. ConclusionsOur results demonstrate the robustness of chemogenomic fitness profiling in yeast, while offering guidelines for performing other high-dimensional comparisons including parallel CRISPR screens in mammalian cells.


2020 ◽  
Author(s):  
Martino Bertoni ◽  
Miquel Duran-Frigola ◽  
Pau Badia-i-Mompel ◽  
Eduardo Pauls ◽  
Modesto Orozco-Ruiz ◽  
...  

AbstractChemical descriptors encode the physicochemical and structural properties of small molecules, and they are at the core of chemoinformatics. The broad release of bioactivity data has prompted enriched representations of compounds, reaching beyond chemical structures and capturing their known biological properties. Unfortunately, ‘bioactivity descriptors’ are not available for most small molecules, which limits their applicability to a few thousand well characterized compounds. Here we present a collection of deep neural networks able to infer bioactivity signatures for any compound of interest, even when little or no experimental information is available for them. Our ‘signaturizers’ relate to bioactivities of 25 different types (including target profiles, cellular response and clinical outcomes) and can be used as drop-in replacements for chemical descriptors in day-to-day chemoinformatics tasks. Indeed, we illustrate how inferred bioactivity signatures are useful to navigate the chemical space in a biologically relevant manner, unveiling higher-order organization in natural product collections, and to enrich mostly uncharacterized chemical libraries for activity against the drug-orphan target Snail1. Moreover, we implement a battery of signature-activity relationship (SigAR) models and show a substantial improvement in performance, with respect to chemistry-based classifiers, across a series of biophysics and physiology activity prediction benchmarks.


2005 ◽  
Vol 15 (20) ◽  
pp. 2047 ◽  
Author(s):  
Paul A. De Bank ◽  
Barrie Kellam ◽  
David A. Kendall ◽  
Kevin M. Shakesheff

Cancers ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 410
Author(s):  
Ilias Mylonis ◽  
Georgia Chachami ◽  
George Simos

Reduced oxygen availability (hypoxia) is a characteristic of many disorders including cancer. Central components of the systemic and cellular response to hypoxia are the Hypoxia Inducible Factors (HIFs), a small family of heterodimeric transcription factors that directly or indirectly regulate the expression of hundreds of genes, the products of which mediate adaptive changes in processes that include metabolism, erythropoiesis, and angiogenesis. The overexpression of HIFs has been linked to the pathogenesis and progression of cancer. Moreover, evidence from cellular and animal models have convincingly shown that targeting HIFs represents a valid approach to treat hypoxia-related disorders. However, targeting transcription factors with small molecules is a very demanding task and development of HIF inhibitors with specificity and therapeutic potential has largely remained an unattainable challenge. Another promising approach to inhibit HIFs is to use peptides modelled after HIF subunit domains known to be involved in protein–protein interactions that are critical for HIF function. Introduction of these peptides into cells can inhibit, through competition, the activity of endogenous HIFs in a sequence and, therefore also isoform, specific manner. This review summarizes the involvement of HIFs in cancer and the approaches for targeting them, with a special focus on the development of peptide HIF inhibitors and their prospects as highly-specific pharmacological agents.


2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Martino Bertoni ◽  
Miquel Duran-Frigola ◽  
Pau Badia-i-Mompel ◽  
Eduardo Pauls ◽  
Modesto Orozco-Ruiz ◽  
...  

AbstractChemical descriptors encode the physicochemical and structural properties of small molecules, and they are at the core of chemoinformatics. The broad release of bioactivity data has prompted enriched representations of compounds, reaching beyond chemical structures and capturing their known biological properties. Unfortunately, bioactivity descriptors are not available for most small molecules, which limits their applicability to a few thousand well characterized compounds. Here we present a collection of deep neural networks able to infer bioactivity signatures for any compound of interest, even when little or no experimental information is available for them. Our signaturizers relate to bioactivities of 25 different types (including target profiles, cellular response and clinical outcomes) and can be used as drop-in replacements for chemical descriptors in day-to-day chemoinformatics tasks. Indeed, we illustrate how inferred bioactivity signatures are useful to navigate the chemical space in a biologically relevant manner, unveiling higher-order organization in natural product collections, and to enrich mostly uncharacterized chemical libraries for activity against the drug-orphan target Snail1. Moreover, we implement a battery of signature-activity relationship (SigAR) models and show a substantial improvement in performance, with respect to chemistry-based classifiers, across a series of biophysics and physiology activity prediction benchmarks.


Science ◽  
2014 ◽  
Vol 344 (6180) ◽  
pp. 208-211 ◽  
Author(s):  
A. Y. Lee ◽  
R. P. St.Onge ◽  
M. J. Proctor ◽  
I. M. Wallace ◽  
A. H. Nile ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document